Citations

Clear

6273 citation(s) found for "To, Andrew".

Determinants of Latent Tuberculosis Treatment Acceptance and Completion in Healthcare Personnel
Swift, Melanie D. , Molella, Robin G., Vaughn, Andrew I. S., Breeher, Laura E. , Newcomb, Richard D. , Abdellatif, Shahnaz, Swift, Melanie D , Breeher, Laura , Murad, M. Hassan

Mayo Clinic

Clinical Infectious Diseases | August 17, 2019 | Volume: 71 | Issue: 2 | Pages: 284-290

10.1093/cid/ciz817 | PMID 31552416 Get It

Abstract Background US public health strategy for eliminating tuberculosis (TB) prioritizes treatment of latent TB infection (LTBI). Healthcare personnel (HCP) are less willing to accept treatment than other populations. Little is known about factors associated with HCP LTBI therapy acceptance and completion. Methods We conducted a retrospective chart review to identify all employees with LTBI at time of hire at a large academic medical center during a 10-year period. Personal demographics, occupational factors, and clinic visit variables were correlated with LTBI treatment acceptance and completion rates using multivariate logistic regression. Results Of 470 HCP with LTBI for whom treatment was recommended, 193 (41.1%) accepted treatment, while 137 (29.1%) completed treatment. Treatment adherence was better with 4 months of rifampin than 9 months of isoniazid (95% vs 68%, P < .005). Increased age of the healthcare worker was independently associated with lower rates of treatment acceptance (odds ratio [95% confidence interval]: 0.97 [0.94–0.99] per year), as was having an occupation of clinician (0.47 [0.26–0.85]) or researcher (0.34 [0.19–0.64]). Male gender was associated with higher treatment acceptance (1.90 [1.21–2.99]). Treatment completion was associated with being from a low- (9.49 [2.06–43.73]) or medium- (8.51 [3.93–18.44]) TB-burden country. Conclusions Geographic and occupational factors affect acceptance and completion of LTBI therapy. Short-course regimens may improve adherence. Physicians, researchers, and HCP from high-TB-burden countries have lower treatment rates than other HCP. Improving LTBI treatment in HCP will require attending to cultural and occupational differences.
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Lindström, Sara , Wang, Lu , Smith, Erin N. , Gordon, William, Vlieg, Astrid van Hylckama , Andrade, Mariza de , Brody, Jennifer A. , Pattee, Jack , Haessler, Jeffrey, Brumpton, Ben , Suchon, Pierre , Chen, Ming‐Huei , Germain, Marine , Wiggins, Kerri L. , Brækkan, Sigrid K. , Armasu, Sebastian M. , Jackson, Rebecca D., Giulianini, Franco, Puurunen, Marja , Ibrahim, Manal , Heckbert, Susan R. , Natarajan, Pradeep , Klarin, Derek , Program, The Million Veteran, Vries, Paul S. de , Sabater‐Lleal, Maria , Group, The CHARGE Hemostasis Working, Bammler, Theo K. , Frazer, Kelly A. , McCauley, Bryan M. , Pankow, James S. , Reiner, Alex P. , Gabrielsen, Maiken E. , Kim, Jihye , McKnight, Barbara, Hansen, J.-B., Heit, John A. , Tang, Weihong , Morange, Pierre‐Emmanuel , Johnson, Andrew D. , Kabrhel, Christopher , Trégouët, David‐Alexandre , Smith, Nicholas L. , Assimes, Themistocles L. , Ballantyne, Christie M. , Hansen, John‐Bjarne , Frazer, Kelly A , de Andrade, Mariza , Assimes, Themistocles L , Wiggins, Kerri L , Ballantyne, Christie M , Natarajan, Pradeep , Braekkan, Sigrid K , Germain, Marine , Brumpton, Ben , Sabater-Lleal, Maria , Pankow, James S , Tang, Weihong , Brody, Jennifer A , Chasman, Daniel I. , Turman, Constance , MacDonald, James W. , Pankratz, Nathan , Nielsen, Jonas Bille , Damrauer, Scott M , Program, The Million Veteran, Huffman, Jennifer E. , Group, The CHARGE Hemostasis Working, Taylor, Kent D. , Deleuze, Jean‐François , O'Donnell, Chris J., Kraft, Peter , Rosendaal, Frits R , Psaty, Bruce M. , Kooperberg, Charles , Hveem, Kristian , Ridker, Paul M.

Mayo Clinic

Blood | August 16, 2019 | Volume: 134 | Issue: 19 | Pages: 1645-1657

10.1182/blood.2019000435 | PMID 31420334 Get It

In this work related to familial aggregation of familial venous thromboembolism, the investigators report genomic and transcriptomic association of 16 novel susceptibility loci for venous thromboembolism.
Reply to Callahan: Identifying “Real” Patients in the Real World
Dempsey, Timothy , Limper, Andrew H. , Dempsey, Timothy M

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 16, 2019 | Volume: 201 | Issue: 2 | Pages: 257-258

10.1164/rccm.201908-1538le | PMID 31419393 Get It

Machine Learning to Predict the Likelihood of Acute Myocardial Infarction
Than, Martin , Sandoval, Yader , Shah, Anoop , Apple, Fred S. , Blankenberg, Stefan , Cullen, Louise , Mueller, Christian, Neumann, Franz–Josef , Twerenbold, Raphael , Westermann, Dirk , Beshiri, Agim , Mills, Nicholas L. , Collaborative, On behalf of the MI, George, Peter M., Richards, Mark , Aldous, Sally, Chapman, Andrew R. , Boeddinghaus, Jasper , Huang, Janel, Cullen, Louise , Mills, Nicholas L , Westermann, Dirk , Richards, Arthur M , Than, Martin , Pickering, John W. , Tsanas, Athanasios , Collaborative, On behalf of the MI, Troughton, Richard W. , Anand, Atul , Greenslade, Jaimi , Parsonage, William , Wildi, Karin , Nestelberger, Thomas , Badertscher, Patrick , Du, Shaoqing, Smith, Stephen W. , Sörensen, Nils Arne , Ojeda, Francisco , Boeddinghaus, Jasper , Blankenberg, Stefan , Neumann, Johannes T , Twerenbold, Raphael

Mayo Clinic

Circulation | August 16, 2019 | Volume: 140 | Issue: 11 | Pages: 899-909

10.1161/circulationaha.119.041980 | PMID 31416346 Get It

Background: Variations in cardiac troponin concentrations by age, sex, and time between samples in patients with suspected myocardial infarction are not currently accounted for in diagnostic approaches. We aimed to combine these variables through machine learning to improve the assessment of risk for individual patients. Methods: A machine learning algorithm (myocardial-ischemic-injury-index [MI 3 ]) incorporating age, sex, and paired high-sensitivity cardiac troponin I concentrations, was trained on 3013 patients and tested on 7998 patients with suspected myocardial infarction. MI 3 uses gradient boosting to compute a value (0–100) reflecting an individual’s likelihood of a diagnosis of type 1 myocardial infarction and estimates the sensitivity, negative predictive value, specificity and positive predictive value for that individual. Assessment was by calibration and area under the receiver operating characteristic curve. Secondary analysis evaluated example MI 3 thresholds from the training set that identified patients as low risk (99% sensitivity) and high risk (75% positive predictive value), and performance at these thresholds was compared in the test set to the 99th percentile and European Society of Cardiology rule-out pathways. Results: Myocardial infarction occurred in 404 (13.4%) patients in the training set and 849 (10.6%) patients in the test set. MI 3 was well calibrated with a very high area under the receiver operating characteristic curve of 0.963 [0.956–0.971] in the test set and similar performance in early and late presenters. Example MI 3 thresholds identifying low- and high-risk patients in the training set were 1.6 and 49.7, respectively. In the test set, MI 3 values were <1.6 in 69.5% with a negative predictive value of 99.7% (99.5–99.8%) and sensitivity of 97.8% (96.7–98.7%), and were ≥49.7 in 10.6% with a positive predictive value of 71.8% (68.9–75.0%) and specificity of 96.7% (96.3–97.1%). Using these thresholds, MI 3 performed better than the European Society of Cardiology 0/3-hour pathway (sensitivity, 82.5% [74.5–88.8%]; specificity, 92.2% [90.7–93.5%]) and the 99th percentile at any time point (sensitivity, 89.6% [87.4–91.6%]); specificity, 89.3% [88.6–90.0%]). Conclusions: Using machine learning, MI 3 provides an individualized and objective assessment of the likelihood of myocardial infarction, which can be used to identify low- and high-risk patients who may benefit from earlier clinical decisions. Clinical Trial Registration: URL: https://www.anzctr.org.au . Unique identifier: ACTRN12616001441404.
Sex Differences in the Use of Statins in Community Practice
Wang, Tracy Y., Xiang, Qun, Goldberg, Anne C. , Robinson, Jennifer G. , Roger, Véronique L. , Louie, Michael J. , Koren, Andrew , Li, Zhuokai , Nanna, Michael G. , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 16, 2019 | Volume: 12 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.118.005562 | PMID 31416347 Get It

Background: Female patients have historically received less aggressive lipid management than male patients. Contemporary care patterns and the potential causes for these differences are unknown. Methods and Results: Examining the Patient and Provider Assessment of Lipid Management Registry—a nationwide registry of outpatients with or at risk for atherosclerotic cardiovascular disease—we compared the use of statin therapy, guideline-recommended statin dosing, and reasons for undertreatment. We specifically analyzed sex differences in statin treatment and guideline-recommended statin dosing using multivariable logistic regression. Among 5693 participants (43% women) eligible for 2013 American College of Cardiology/American Heart Association Cholesterol Guideline–recommended statin treatment, women were less likely than men to be prescribed any statin therapy (67.0% versus 78.4%; P <0.001) or to receive a statin at the guideline-recommended intensity (36.7% versus 45.2%; P <0.001). Women were more likely to report having previously never been offered statin therapy (18.6% versus 13.5%; P <0.001), declined statin therapy (3.6% versus 2.0%; P <0.001), or discontinued their statin (10.9% versus 6.1%; P <0.001). Women were also less likely than men to believe statins were safe (47.9% versus 55.2%; P <0.001) or effective (68.0% versus 73.2%; P <0.001) and more likely to report discontinuing their statin because of a side effect (7.9% versus 3.6%; P <0.001). Sex differences in both overall and guideline-recommended intensity statin use persisted after adjustment for demographics, socioeconomic factors, clinical characteristics, patient beliefs, and provider characteristics (adjusted odds ratio, 0.70; 95% CI, 0.61–0.81; P <0.001; and odds ratio, 0.82; 95% CI, 0.73–0.92; P <0.01, respectively). Sex differences were consistent across primary and secondary prevention indications for statin treatment. Conclusions: Women eligible for statin therapy were less likely than men to be treated with any statin or guideline-recommended statin intensity. A combination of women being offered statin therapy less frequently, while declining and discontinuing treatment more frequently, accounted for these sex differences in statin use.
Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation
Alnsasra, Hilmi , Schettle, Sarah , Pereira, Naveen L. , Frantz, Robert P. , Edwards, Brooks S., Clavell, Alfredo L. , Maltais, Simon, Daly, Richard C. , Stulak, John M., Rosenbaum, Andrew , Behfar, Atta , Kushwaha, Sudhir S. , Asleh, Rabea , Schettle, Sarah D., Rosenbaum, Andrew N , Behfar, Atta , Frantz, Robert P

Mayo Clinic

Journal of the American Heart Association | August 14, 2019 | Volume: 8 | Issue: 16 | Pages: No page available

10.1161/jaha.119.012073 | PMID 31411097 Get It

Background Diastolic pulmonary gradient ( DPG ) was proposed as a better marker of pulmonary vascular remodeling compared with pulmonary vascular resistance ( PVR ) and transpulmonary gradient ( TPG ). The prognostic significance of DPG in patients requiring a left ventricular assist device ( LVAD ) remains unclear. We sought to investigate whether pre‐ LVAD DPG is a predictor of survival or right ventricular ( RV ) failure post‐ LVAD . Methods and Results We retrospectively reviewed 268 patients who underwent right heart catheterization before LVAD implantation from 2007 to 2017 and had pulmonary hypertension because of left heart disease. Patients were dichotomized using DPG ≥7 mm Hg, PVR ≥3 mm Hg, or TPG ≥12 mm Hg. The associations between these parameters and all‐cause mortality or RV failure post LVAD were assessed with Cox proportional hazards regression and Kaplan–Meier analyses. After a mean follow‐up time of 35 months, elevated DPG was associated with increased risk of RV failure (hazard ratio [ HR ]: 3.30; P =0.004, for DPG ≥7 versus DPG <7), whereas elevated PVR ( HR 1.85, P =0.13 for PVR ≥3 versus PVR <3) or TPG ( HR 1.47, P =0.35, for TPG ≥12 versus TPG <12) were not associated with the development of RV failure. Elevated DPG was not associated with mortality risk ( HR 1.16, P =0.54, for DPG ≥7 versus DPG <7), whereas elevated PVR , but not TPG , was associated with higher mortality risk ( HR 1.55; P =0.026, for PVR ≥3 versus PVR <3). Conclusions Among patients with pulmonary hypertension because of left heart disease requiring LVAD support, elevated DPG was associated with RV failure but not survival, while elevated PVR predicted mortality post LVAD implantation.
Position-Specific Body Composition Values in Female Collegiate Rugby Union Athletes
Zabriskie, Hannah A. , Stecker, Richard A., Currier, Brad S. , Moon, Jessica M. , Richmond, Scott R., Zabriskie, Hannah A , Currier, Bradley S , Harty, Patrick S. , Jagim, Andrew R. , Kerksick, Chad M.

Mayo Clinic

Journal of Strength & Conditioning Research | August 9, 2019 | Volume: 35 | Issue: 11 | Pages: 3158-3163

10.1519/jsc.0000000000003314 | PMID 31403573 Get It

Abstract Harty, PS, Zabriskie, HA, Stecker, RA, Currier, BS, Moon, JM, Richmond, SR, Jagim, AR, and Kerksick, CM. Position-specific body composition values in female collegiate rugby union athletes. J Strength Cond Res 35(11): 3158–3163, 2021—Rugby union is a full-contact, intermittent team sport. Anthropometric characteristics of rugby union athletes have been shown to influence suitability for a given position and affect performance. However, little anthropometric data exist in female rugby union athletes. Thus, the purpose of this study was to report position-specific anthropometric, body composition, and bone density values in female collegiate rugby union athletes and to identify between-position differences in these variables. This investigation was a cross-sectional study involving 101 female collegiate rugby union athletes, categorized as forwards and backs as well as by position (props, hookers, locks, flankers, number 8 forwards, halfback, fly-half, centers, wings, and fullbacks). Anthropometric characteristics of all athletes were measured, and body composition was assessed via dual-energy x-ray absorptiometry. Outcome variables included age, height, body mass, BMI, body fat percentage, fat mass (FM), FM index, fat-free mass (FFM), FFM index, lean soft tissue, bone mineral content, bone mineral area, and bone mineral density. Anthropometric and body composition differences between forwards and backs were identified via independent t -tests and Mann-Whitney U tests, depending on normality of the variable. Between-position differences were assessed using one-way analysis of variances (ANOVAs) with Tukey post-hoc comparisons or Welch's ANOVA with Dunnett's T3 post-hoc test. Significant differences ( p < 0.014) were identified between forwards and backs for every anthropometric variable, with forwards displaying greater height (167.7 ± 7.2 cm), body mass (81.5 ± 15.1 kg), and body fat percentage (28.2 ± 6.1%) relative to backs (164.5 ± 5.1 cm; 64.5 ± 7.7 kg; 21.9 ± 3.7%). Likewise, significant differences were identified for every anthropometric variable between several positions ( p < 0.01). Significant ( p < 0.05) interposition differences were identified within the subgroup of forwards, but not within the subgroup of backs. The present investigation is the first to report position-specific anthropometric and body composition data in female collegiate rugby union athletes. The results of this study can be used by rugby union coaches for recruiting and personnel decisions, to determine a player's suitability for a given position, and to further inform training and nutritional interventions in this population.
Elbow Injuries in National Collegiate Athletic Association Athletes: A 5-Season Epidemiological Study
Patel, Karan A. , Makovicka, Justin L. , Chung, Andrew S. , Hydrick, Thomas C. , Ginn, Jessica, Hartigan, David E. , Hassebrock, Jeffrey D. , Patel, Karan , Chung, Andrew , Tummala, Sailesh V , Tummala, Sailesh V. , Chhabra, Anikar

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 8, 2019 | Volume: 7 | Issue: 8 | Pages: No page available

10.1177/2325967119861959 | PMID 31448298 Get It

Background: Little research has focused on the rates and patterns of elbow injuries in National Collegiate Athletic Association (NCAA) student-athletes. Purpose: To describe the epidemiological patterns of elbow injuries in NCAA athletes during 5 seasons over the academic years 2009 through 2014 using the NCAA Injury Surveillance Program (NCAA-ISP) database. Study Design: Descriptive epidemiology study. Methods: A voluntary convenience sample of NCAA varsity teams from 11 sports was examined to determine the rates and patterns of elbow injuries. Rates and distributions of elbow injuries were identified within the context of sport, event type, time in season, mechanism, time lost from sport, surgical treatment, and injury type. Rates of injury were calculated as the number of injuries divided by the total number of athlete-exposures (AEs). An AE was defined as any student participation in 1 NCAA-sanctioned practice or competition with an inherent risk of exposure to potential injury. Injury rate ratios (IRRs) and injury proportion ratios (IPRs) were then calculated to compare the rates within and between sports by event type, season, sex, mechanism, surgical treatment, and time lost from sport. Comparisons between sexes were made using only sports data that had both male and female samples. Results: Overall, 373 elbow injuries were reported in the NCAA-ISP data set during the 2009-2010 through 2013-2014 academic years among 11 varsity sports. The overall rate of injury was 1.76 per 10,000 AEs. The rate of elbow injuries in men was 0.74 per 10,000 AEs, while women experienced injuries at a rate of 0.63 per 10,000 AEs. In sex-comparable sports, men were 1.17 times more likely to experience an elbow injury compared with women. Men’s wrestling (6.00/10,000 AEs) and women’s tennis (1.86/10,000 AEs) were the sports with the highest rates of elbow injuries by sex, respectively. The top 3 highest injury rates overall occurred in men’s wrestling, baseball, and tennis. Elbow injuries were 3.5 times more likely to occur during competition compared with practice. Athletes were 0.76 times less likely to sustain an elbow injury during the preseason compared with in-season. Contact events were the most common mechanism of injury (67%). For sex-comparable sports, men were 2.41 times more likely than women to have contact as their injury mechanism (95% CI, 0.78-7.38). The majority of athletes missed less than 24 hours of participation time (67%), and only a minority (3%) of patients with elbow injuries went on to have surgical intervention. Elbow ulnar collateral ligament injuries were most common (26% of total injuries). Conclusion: Analysis of the study data demonstrated a significant rate of elbow injuries, 1.76 injuries per 10,000 AEs in NCAA collegiate athletes. Higher injury rates can be expected in males within sex-comparable sports. Elbow injuries are most common in the setting of competitions and most commonly occur secondary to contact-type mechanisms. Injuries were more likely to occur during in-season play. The majority of injuries required less than 24 hours of time away from sport and did not require surgical intervention.
Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy
Dodge, Andrew , Ng, Kimmie , Kato, Shumei , Ahn, Daniel H. , Nagy, Rebecca J. , Ciombor, Kristen K. , Ou, Fang‐Shu , Zemla, Tyler , Wu, Christina , Pedersen, Katrina S. , Kasi, Pashtoon Murtaza , Lanman, Richard B. , Kopetz, Scott , Strickler, John H. , Bekaii‐Saab, Tanios

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: LB-235-LB-235

10.1158/1538-7445.am2019-lb-235 Get It

Abstract Background: Colorectal cancer (CRC) is the second leading cause of cancer death among men and women in the United States, and additional treatment strategies are needed for patients with advanced disease. Prospective therapeutic studies based on tissue-detected genomic targets such as ERBB2 (HER2), BRAF V600E, gene rearrangements/fusions, and microsatellite instability (MSI) have demonstrated clinical benefit for mCRC patients. Although correlative studies and/or retrospective case series utilizing circulating cell-free DNA (cfDNA) next generation sequencing (NGS) have shown that plasma detection of these genomic targets shows promise in mCRC, prospective studies are lacking. We hypothesize that comprehensive genomic profiling of cfDNA will identify actionable targets and improve outcomes for patients with mCRC. Methods: COLOMATE (Colorectal Cancer and Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy; NCT03765736) is a phase II umbrella screening protocol sponsored by the Academic and Community Cancer Research United (ACCRU) consortium. This study utilizes Guardant360™ (Guardant Health, Redwood City, CA) - a blood-based targeted NGS panel - to identify actionable genomic alterations in mCRC patients and to assess the impact of molecularly assigned therapy accordingly under its individual companion studies. Eligible mCRC patients must have progressed on, been intolerant to, or have a contraindication to treatment with a fluoropyrimidine, oxaliplatin, irinotecan, anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) and anti-epidermal growth factor receptor (EGFR) mAbs if RAS wild-type. Companion studies are dynamic and currently include those for patients whose tumors are either RAS/BRAF wild-type, HER2 amplified, FGFR altered, RAS mutated, or without any known actionable alteration. Additional companion studies are under active development. The primary objectives of this study are to perform blood-based genomic profiling on patients with treatment refractory mCRC to facilitate accrual to molecularly assigned therapies, and to obtain patient-matched tumor tissue and cell free DNA from peripheral blood to facilitate clinically annotated genomic analyses. Secondary correlative objectives are to explore mechanisms of acquired resistance to molecularly assigned therapy and to explore the correlation between cfDNA mutational burden (allele frequency, copy number) and clinical outcomes such as objective response rate, progression-free survival, and overall survival. Citation Format: Kristen K. Ciombor, Fang-Shu Ou, Andrew Dodge, Tyler Zemla, Christina Wu, Kimmie Ng, Katrina Pedersen, Shumei Kato, Pashtoon M. Kasi, Daniel Ahn, Rebecca Nagy, Richard Lanman, Scott Kopetz, John H. Strickler, Tanios Bekaii-Saab. COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-235.
Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays
McCarthy, Cian P. , Raber, Inbar , Chapman, Andrew R. , Sandoval, Yader , Apple, Fred S. , Mills, Nicholas L. , Mills, Nicholas L , Januzzi, James Louis

Mayo Clinic

JAMA Cardiology | August 7, 2019 | Volume: 4 | Issue: 10 | Pages: 1034

10.1001/jamacardio.2019.2724 | PMID 31389986 Get It